A large-scale study suggests chloroquine and hydroxychloroquine don't help treat COVID-19, and it may even be harmful. Today, peer-reviewed journal The Lancet published a paper analyzing data from thousands of patients who took the drugs. Their outcomes were no better than those of people who didn't in fact, they were more likely to die or develop an irregular heartbeat.
The analysis covers a registry of roughly 15,000 patients across multiple continents, all of whom were given either hydroxychloroquine, chloroquine, or one of those drugs paired with a class of antibiotics called macrolides. It compares the group with roughly 81,000 patients who were not given the drugs. The results weren't encouraging. People treated with either drug had a higher mortality rate, as well as an increased risk of developing ventricular arrhythmia.
Both chloroquine and hydroxychloroquine were linked to worse outcomes even after controlling for other risk factors like age, preexisting health conditions, and being a current smoker. Researchers completely excluded patients who were treated later than 48 hours after diagnosis, as well as anyone taking remdesivir, a different experimental treatment.
This doesn't conclusively prove the drugs are dangerous. The authors including researchers from Harvard Medical School, the University Hospital of Zurich, the University of Utah, and Surgisphere Corporation warn there might be other variables that weren't accounted for. But there was "no evidence" that the medications were helpful. And the researchers stress an urgent need for controlled clinical trials (where people are randomly assigned to take the drug or not), not just studies like this one that passively observe patients, to provide more information.
Chloroquine and hydroxychloroquine initially looked like promising treatments for COVID-19. The evidence consisted of preliminary studies involving a few dozen patients, though, and one has since been withdrawn for revision. Later research has cast doubt on their results. A New England Journal of Medicine article from earlier this month compared roughly 800 patients who took hydroxychloroquine to around 560 who didn't, finding "no significant association" between the drug's use and survival rates.
Despite this, chloroquine and hydroxychloroquine have become touchstones in a culture war. They've been championed with minimal evidence by Tesla CEO Elon Musk, Fox News, and President Donald Trump, who announced earlier this week that he's been taking hydroxychloroquine to prevent COVID-19. (Conversely, Trump has refused to wear masks in public, despite tentative evidence that they slow COVID-19's spread.) Some doctors have complained that the drugs' politicization made it more difficult to conduct research, and the hype has caused shortages among people who take them for other conditions like lupus and rheumatoid arthritis.
The Lancet study doesn't examine whether the drugs might prevent COVID-19, and it specifically looks at health risks in people who are already sick. These medications are currently approved for use treating autoimmune diseases and preventing malaria, although they have known side effects including arrhythmia. Clinical trials to see if they can prevent COVID-19 are still underway.
This research probably won't settle the political debate over hydroxychloroquine and chloroquine. Trump's announcement that he's taking one of the drugs has sparked renewed interest among supporters, including a defensive tweet from Trump's campaign manager promoting a misleading statistical analysis. The president initially promoted the drugs as a miracle cure and if such a cure exists, it's far easier to order the end of shelter-in-place policies and other containment measures for the novel coronavirus.
As it stands, there's no proven treatment for COVID-19, and we're months or years away from a novel coronavirus vaccine, although several promising options are being researched. But discovering that a specific treatment doesn't work is also valuable, especially if that treatment turns out to be worse than taking nothing at all. While today's study doesn't take chloroquine and hydroxychloroquine off the table, it provides additional, clear evidence about their usefulness and their risks.
Japan is moving ahead with plans to land a spacecraft on Phobos, one of Mars' moons. If successful, the mission would mark the first time any country has touched down on the surface of the Martian moon and potentially the first round-trip mission to the Mars system. Japan's space agency, JAXA, announced today that the Martian Moons Exploration (MMX) project had officially moved into the development phase. This means that the team will start working on the hardware and software for the mission ahead of a planned launch in 2024. MMX will take off sometime in 2024 and arrive at Mars around 2025. It will spend the next three years surveying both moons of Mars, Phobos and Deimos, creating detailed maps of their surfaces. During that time, MMX will also land on Phobos and take a sample, digging...Read More
You've uncle a grandfather, or even a brother that went to serve. A few of those veterans still suffer now from a post-traumatic stress disorder and suffered. Back then was not even a diagnosis for post-traumatic stress disorder, or it did not have a name and wasn't a thing that is known if there was. Even though they could not differentiate themselves what they experienced A lot of them turned to self-medicate. They wake up in the center of the night or cannot sleep at all. They turn to their fix - their just source of relaxation and just way of easing the pain. The simple fact that many of these veterans were groomed to believe that emotions or showing emotion were an indicator of weakness chemicals an issue today that experts are seeing. Data in the National Survey on Drug Use and...Read More
Huawei has been given yet another reprieve from the Trump administration's ban on its products, according to Commerce Department documents filed today. Earlier this year, citing concerns of electronic espionage, the United States moved to restrict the purchase of equipment from "foreign adversaries." The decision took aim directly at Huawei, as officials expressed concern that the Chinese government could exploit the China-based company to spy on Americans. (The company has denied any wrongdoing.) But after the initial announcement, Huawei and its subsidiaries were quickly granted licenses to continue work in the US. And after one 90-day delay ended in August, Commerce Secretary Wilbur Ross granted another, giving rural wireless carriers that rely on Huawei products time to change their...Read More
Three of China’s biggest smartphone makers are working together on a new wireless file transfer protocol that will work between their respective devices. Xiaomi’s MIUI, Oppo’s ColorOS, and Vivo’s FuntouchOS — all based on Android — will integrate the peer-to-peer system, according to a WeChat post by Xiaomi’s official MIUI account. The protocol will use Bluetooth to pair devices and should be capable of transfer speeds of up to 20MB/s, which suggests it uses Wi-Fi on the backend, like Apple’s proprietary AirDrop system. Xiaomi’s post says other smartphone manufacturers can apply to join the presently allied trio. A beta version of the service should be released by the end of this month. Google has attempted to launch AirDrop-style services for Android in the past, with...Read More
Last month, Valve announced a beta of Steam Remote Play Together, which let you play local multiplayer games over the internet with your friends across Windows, Linux, and macOS computers. Today, Remote Play Together is officially available for everyone, with a what could be a really cool new feature — you can play with your friends using iOS and Android devices as well. According to Valve, the host player just needs to install and start the game, and friends on PC can join in via Steam Remote Play or on mobile with the Steam Chat and Steam Link apps. Only the host needs to actually own the game, which is nice. We haven't been able to test Remote Play Together ourselves with iOS and Android clients yet, so we don't know if network latency might be an issue when you're playing an...Read More
Libra, and the nonprofit association that will oversee it raises questions about the future of global banking and Facebook’s role in it. But behind Facebook’s ambitions to create a quasi-nation state ruled by mostly corporate interests is a secret weapon, one the company hopes it can use to create another platform used by billions of people — and generate enormous new revenue streams along the way. It’s called Calibra, and it’s a new subsidiary of Facebook the company is launching to build financial services and software on top of the Libra blockchain. At first blush, Calibra resembles a fairly standard payments company — but its tight integration with Facebook’s enormous user base could give it a significant advantage over any rivals. Thanks to its proximity to the...Read More
A chilling Christmas greeting to the West has come from Vladimir Putin today in the form of a 2019 calendar from his burgeoning military machine. The Russian Defence Ministry view of next year begins with a snowy January view of a hulking Topol-M intercontinental mobile missile system captioned cheerfully: “Cargo delivery to anywhere in the world.” Another icy calendar greeting comes in September with a picture showing a uniformed female sniper taking aim to shoot. “Some women can blow your head away,” reads the caption. The calendar was unveiled in apparent deliberate timing as the West marks Christmas Day. For Russians 25 December is a normal working day and their main seasonal celebration comes at New Year, the moment when Grandfather Frost - as Santa is known here - brings...Read More
Microsoft co-founder Bill Gates has been reflecting on his time at the company when crucial decisions were made over its mobile operating system. During a recent interview at Village Global, a venture capital firm, Gates revealed his “greatest mistake ever” was Microsoft missing the Android opportunity: “In the software world, particularly for platforms, these are winner-take-all markets. So the greatest mistake ever is whatever mismanagement I engaged in that caused Microsoft not to be what Android is. That is, Android is the standard non-Apple phone platform. That was a natural thing for Microsoft to win. It really is winner take all. If you’re there with half as many apps or 90 percent as many apps, you’re on your way to complete doom. There’s room for exactly one non-Apple...Read More
President Donald Trump's tentative trade deal with China, announced earlier today, has saved Apple from raising the prices or eating those price hikes itself, of some of its most popular products, including the iPhone. According to Bloomberg, which cites Wedbush Securities analyst Dan Ives, Apple's top iPhone models could have been hit with a 15 percent tariff, which equates to a bump in the price of around $150 for the base model iPhone 11 Pro, if the trade deal had not been reached. The tariffs were set to go into effect on December 15th and would have impacted the iPhone, the iPad, and the MacBook line, among other products. "Trump delivered an early Christmas present to Apple," Ives said in a note to investors obtained by Bloomberg. "If this tariff went through it would have been a...Read More
Microsoft has been granted a license to export software to Huawei once again. The software giant was caught up in a long line of US-based technology companies that have been forced to comply with President Trump's executive order to crack down on Chinese tech companies. “On November 20th, the US Department of Commerce granted Microsoft's request for a license to export mass-market software "to Huawei," says a Microsoft spokesperson in a statement to Bloomberg. "We appreciate the department's action in response to our request." It’s not immediately clear what "mass-market" refers to, but Microsoft sells Windows and Office licenses to Huawei. It's likely that Microsoft is at least able to sell Windows licenses to Huawei once again, which will help with Huawei's server solutions and its...Read More